Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized controlled trial which will be conducted to determine
whether sub-dissociative dose ketamine (SDDK) can improve pain control in subjects with
chronic pain syndrome presenting to the emergency department with exacerbation of their
chronic pain. The investigators also aim to determine whether use of SDDK can reduce the
amount of subsequent opioid pain medications required for adequate pain relief in this
population.
Phase:
Phase 3
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center